Drug Approval | May 10, 2024
Cipla receives 1 observation from USFDA for Kurkumbh facility
The company is committed to address this observation comprehensively within stipulated time
The company is committed to address this observation comprehensively within stipulated time
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
With this, for all our USFDA facilities, EIRs are in place
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
FDA has concluded that this inspection is 'closed'
Sun Pharma's Dadra facility receives OAI status from US FDA
The company will respond to the Warning Letter within the stipulated timelines
These observations are procedural in nature and will be responded within the stipulated time
Subscribe To Our Newsletter & Stay Updated
